AccessibilityHelpAbout Us
Island Pharmaceuticals logo

Island Pharmaceuticals(ASX) ILA

Market CapA$130.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-8%
5 Year+42%
1 Year+47%
1 Month-2%
A$0.44
-2.22%
-0.01Today
Island Pharmaceuticals last closing stock price
MetricPriceDate
Last closeAUD 0.442026-09-08
Island Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.53%AUD 0.432026-09-01
1 month-2.22%AUD 0.452026-08-07
3 month+20.55%AUD 0.372026-06-10
Year to date+2.33%AUD 0.432025-12-31
1 year+46.67%AUD 0.302025-09-08
3 year+443.21%AUD 0.082023-09-08
5 year+41.94%AUD 0.312021-09-09
Since inception-7.69%AUD 0.492021-04-13

Island Pharmaceuticals Financials at a Glance

Market Cap

A$130.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$118.91K

Net Income (TTM)

-A$13.76M

EPS (TTM)

-A$0.04

P/E Ratio

-12.22

Dividend

A$0.00

Beta (Volatility)

-0.15 (Low)

Price

A$0.44

Volume

0

Open

A$0.45

Previous Close

A$0.44

Daily Range

A$0.44 - A$0.45

52-Week Range

A$0.28 - A$0.63

Estimated Earnings Date

Mar 3, 2027

ILA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Island Pharmaceuticals

Island Pharmaceuticals Limited is a biotechnology company focused on drug discovery and repurposing, particularly for viral infections. The company is developing ISLA-101, a therapeutic agent aimed at preventing and treating dengue fever and other mosquito-borne illnesses.

Products and Services
  • ISLA-101 for dengue fever prevention and treatment
  • Research collaborations with Monash University and Griffith University
  • Access to a drug library through Compounds Australia for drug repurposing
Growth Outlook
  • Strategic partnerships enhance research capabilities and drug development
  • Upcoming Phase II clinical study for ISLA-101 expected to drive interest
  • Strong cash position supports ongoing research and development efforts
Financial Highlights
  • Recent quarterly revenue of AUD 0, reflecting ongoing development phase
  • Cash and cash equivalents of AUD 12.87 million as of June 2026
  • Current ratio of 24.62 indicates strong liquidity position
Island Pharmaceuticals Limited operates in a dynamic sector with a clear focus on addressing significant health challenges posed by viral infections. The company's lead product, ISLA-101, is positioned to meet a critical need in the market, particularly in regions affected by dengue fever. Collaborations with esteemed institutions like Monash University and Griffith University not only bolster research capabilities but also enhance the potential for successful drug development. The financial position of Island Pharmaceuticals is noteworthy, with a substantial cash reserve that supports ongoing research and development activities. The current ratio indicates a robust liquidity position, allowing the company to navigate the complexities of the biotechnology landscape effectively. As the company prepares for its Phase II clinical study, investor interest may grow, particularly given the increasing global focus on viral diseases. Overall, Island Pharmaceuticals Limited presents a compelling opportunity for investors interested in the biotechnology sector, particularly those focused on innovative solutions for viral infections.
AI Generated • Aug 30, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

David Foster, PhD

Website

www.islandpharmaceuticals.com

Headquarters

Hawthorn East, VIC 3123, AU

ILA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-95.50%

Return on Capital

-78.89%

Return on Assets

-70.33%

Earnings Yield

-8.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$130.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

296.10M

Volume

0

Avg. Volume

267.92K

Financials (TTM)

Gross Profit

-A$1.39M

Operating Income

-A$15.98M

EBITDA

-A$14.59M

Operating Cash Flow

-A$7.60M

Capital Expenditure

-A$6.00

Free Cash Flow

-A$7.60M

Cash & ST Invst.

A$12.87M

Total Debt

A$0.00

Island Pharmaceuticals Performance Analysis

Island Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Island Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-68.0%
Q42025-06-30-77.2%
Q22025-12-31-100.0%
Q42026-06-30N/A
Island Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.038.4%
20242024-06-30AUD -0.03-1.9%
20252025-06-30AUD -0.02-28.7%
20262026-06-30AUD -0.0461.1%
Island Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3137.8%
Q42025-06-30-9.3%
Q22025-12-31-62.4%
Q42026-06-3010.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$52.64K

+92.4%

Gross Margin

0.00%

N/A

Market Cap

A$130.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-A$5.03M

-194.4%

EBITDA

-A$5.61M

-320.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$12.87M

+675.2%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$285.58K

-67.9%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

-100.0%

Return on Assets

-70.33%

N/A

Return on Invested Capital

-78.89%

N/A

Free Cash Flow

-A$2.85M

-57.3%

Operating Cash Flow

-A$2.85M

-57.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RCE.AXRecce Pharmaceuticals Ltd
A$0.37+2.78%
ATH.AXAlterity Therapeutics Limited
A$0.49-2.02%
BIO.AXBiome Australia Limited
A$0.35-4.17%
ALA.AXArovella Therapeutics Limited
A$0.06-4.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$104.47+0.09%
NVDANvidia
$225.73-0.02%
ATAIAtaiBeckley
$7.28-0.01%
NOKNokia
$10.65+0.06%

Questions About ILA

What is the current price of Island Pharmaceuticals?

Island Pharmaceuticals is trading at A$0.44 per share.

What is the 52-week range for Island Pharmaceuticals?

Over the past 52 weeks, Island Pharmaceuticals has traded between A$0.28 and A$0.63.

How much debt does Island Pharmaceuticals have?

As of the most recent reporting period, Island Pharmaceuticals reported total debt of A$0.00.

How much cash does Island Pharmaceuticals have on hand?

Island Pharmaceuticals reported A$12.87M in cash and cash equivalents in its most recent financial results.

What is Island Pharmaceuticals’s dividend yield?

Island Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services